Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease.

Autor: Wormser GP; Division of Infectious Diseases, New York Medical College, 40 Sunshine Cottage Road, Skyline Office #2N-F05, 10595, Valhalla, NY, USA. gwormser@nymc.edu., Barbour AG; Departments of Medicine and Microbiology & Molecular Genetics, University of California Irvine, 92697, Irvine, CA, USA.
Jazyk: angličtina
Zdroj: Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2023 Apr; Vol. 135 (7-8), pp. 185-189. Date of Electronic Publication: 2019 May 10.
DOI: 10.1007/s00508-019-1505-6
Abstrakt: Vancomycin is active in vitro and in vivo in mouse systems against Lyme disease borrelia; however, there are no published data on the efficacy of vancomycin in patients with Lyme disease and no convincing theoretical advantages of vancomycin over the currently used and highly effective orally administered antimicrobial agents, including doxycycline, amoxicillin and cefuroxime axetil. In addition, vancomycin may cause a wide variety of potentially serious adverse effects and requires the placement of an intravenous catheter. It is concluded that vancomycin is a much less attractive option for the treatment of patients with early Lyme disease (or any other manifestation of Lyme disease), compared with the antimicrobials currently being used. Based on available evidence, clinical studies to evaluate the safety and efficacy of vancomycin for Lyme disease cannot be recommended.
(© 2019. Springer-Verlag GmbH Austria, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: